Notably, the anti‐amnestic S1R ligand rivastigmine is a United States Food and Drug Administration (FDA) ‐approved drug, currently under preclinical studies for mild or moderate AD.47, 48. This evidence concerns the gene TMBIM4 and Alzheimer disease.